|
Real-time Estimate
Cboe BZX
10:18:44 2026-10-22 EDT
|
5-day change | 1st Jan Change | ||
| 1.018 USD | -0.20% |
|
+2.00% | -93.61% |
| 25-05-30 | Cara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 | CI |
| 25-04-14 | Cara Therapeutics, Inc.(NasdaqCM:CARA) dropped from NASDAQ Composite Index | CI |
| Market Cap | 24.33M 21.68M 20.07M 18.17M 34.23M 2.3B 34.63M 241M 94.44M 1.21B 91.28M 89.37M 3.85B | P/E 2023 |
-0.34x | P/E 2024 | -0.39x |
|---|---|---|---|---|---|
| Enterprise Value | 30.88M 27.51M 25.47M 23.05M 43.43M 2.91B 43.95M 305M 120M 1.53B 116M 113M 4.88B | EV / Sales 2023 |
-0.82x | EV / Sales 2024 | 4.84x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
| 1 day | +2.82% | ||
| Current month | -93.61% | ||
| Current year | -93.61% |
| 3 years | 1 |  | 50.4 |
| 5 years | 1 | | 681.48 |
| 10 years | 1 | | 1,067.3 |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 20.97M 18.68M 17.3M 15.65M 29.49M 1.98B 29.84M 207M 81.38M 1.04B 78.66M 77.02M 3.31B | 7.14M 6.36M 5.89M 5.33M 10.04M 673M 10.16M 70.6M 27.7M 354M 26.77M 26.22M 1.13B |
| Net income | -119M -106M -97.77M -88.48M -167M -11.18B -169M -1.17B -460M -5.88B -445M -435M -18.73B | -70.87M -63.15M -58.47M -52.91M -99.68M -6.69B -101M -701M -275M -3.52B -266M -260M -11.2B |
| Net Debt | -57.59M -51.32M -47.51M -43M -81.01M -5.43B -81.97M -570M -224M -2.86B -216M -212M -9.1B | 6.54M 5.83M 5.4M 4.89M 9.21M 618M 9.32M 64.74M 25.4M 325M 24.55M 24.04M 1.03B |
| Date | Price | Change |
|---|---|---|
| 26-10-22 | US$1.020 | 0.00% |
| 26-10-21 | US$1.020 | +2.82% |
| 26-10-20 | US$0.9920 | +2.27% |
| 26-10-19 | US$0.9700 | -3.96% |
| 26-10-16 | US$1.010 | -5.61% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- CARA Stock
Select your edition
All financial news and data tailored to specific country editions
